Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 15/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14687856 | 0.85 | F2R (0.49) | F2RMAP4K4 | |
| SCHEMBL2553880 | 0.85 | F2R (0.49) | F2RMAP4K4 | |
| SCHEMBL8233042 | 0.83 | F2R (0.49) | F2RTAAR1ESR2CYP17A1CYP3A4 | |
| SCHEMBL30679648 | 0.81 | CNR2 (0.47) | F2RTAAR1MAP4K4 | |
| SCHEMBL26031105 | 0.81 | HSD17B1 (0.60) | ESR2CYP17A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL5247452 | 0.81 | CNR2 (0.47) | F2RTAAR1MAP4K4 | |
| SCHEMBL12284810 | 0.81 | F2R (0.46) | F2RMAP4K4 | |
| SCHEMBL30893537 | 0.81 | KCNJ1 (0.44) | — | |
| SCHEMBL16761877 | 0.81 | KCNJ1 (0.44) | — | |
| SCHEMBL29893944 | 0.81 | KCNJ1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| EP-2558465-B1 | TRICYCLIC PYRIDYL-VINYL-PYROLES AS PAR1 INHIBITORS | SANOFI SA (FR) | 2014-12-17 | — | — | EP | disclosed |
| EP-2558465-B1 | TRICYCLIC PYRIDYL-VINYL-PYROLES AS PAR1 INHIBITORS | SANOFI SA (FR) | 2014-12-17 | — | — | EP | disclosed |
| US-8871798-B2 | Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors | SANOFI (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| WO-2011128420-A1 | PYRIDYL-VINYL PYRAZOLOQUINOLINES AS PAR1 INHIBITORS | SANOFI (FR) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128421-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128421-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2011-10-20 | — | — | WO | disclosed |
| EP-2062890-B1 | Tricyclic thrombin receptor antagonist | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | F2R 4409/4885TAAR1 1770/4885ESR2 1138/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | F2R 4572/4885TAAR1 3547/4885ESR2 1885/4885 |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | F2R, F2RL1, F2RL3 | F2R 1/4885TAAR1 2165/4885ESR2 1796/4885 |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | F2R, F2RL1, F2RL3 | F2R 1/4885TAAR1 1563/4885ESR2 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.